TABLE 1.
Complementation of growth defect correlates with m7G formation in tRNAPhe in vitro and in vivo
| Strain | Plasmid | Growth defect complementationa | m7G activity in vitrob | % of m7G in vivoc | |
| 1a | TRM8 | Yes | +++ | 110 | |
| 1b | trm8 (G/A) | Yes | + | 5.1 | |
| 1c | trm8-Δ | trm8 (GG/AA) | No | − | not detectedd |
| 1d | trm8 (GGG/AAE) | No | − | not detected | |
| 1e | trm8 (1–39Δ) | Yes | ++ | 39 | |
| 3a | YggH | Yes | +++ | 119 | |
| 3b | yggH (G/A) | No | − | not detected | |
| 3c | trm8-Δ | yggH (GG/AA) | No | − | not detected |
| 4a | trm82-Δ | TM0925 | Yes | +++ | 112 |
| 4b | tm0925 (G/A) | Yes | +++ | 28 | |
| 4c | tm0925 (GG/AA) | Yes | + | 5.5 | |
| 5 | vect. | No | − | not detected | |
| 6 | Wild type | vect. | Yes | +++ | 100 |
aAs shown in Figure 2 ▶.
bAs shown in Figure 3A ▶.
cAs determined by HPLC analysis of m7G content of tRNAPhe purified from the corresponding strain. 100% corresponds to m7G content of tRNAPhe purified from the wild-type strain (in this experiment: 0.80 m7G per tRNA).
dDetection limit of m7G was 2% of the wild-type amount.